Allison Luo
Bristol-Myers Squibb
23 Papers
76 Citations
Allison Luo is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Placebo & Ulcerative colitis. The author has an hindex of 11, co-authored 21 publications.
Chat about Author
Papers
A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis.
Michael Yellin,Igor Paliienko,Andra Balanescu,Semen Ter-Vartanian,Vira Tseluyko,Li-An Xu,Xiaolu Tao,Pina M. Cardarelli,Heidi N. Leblanc,Geoff Nichol,Codrina Ancuta,Rodica Chirieac,Allison Luo +12 more
TL;DR: This is the first study to demonstrate clinical efficacy of a chemokine inhibitor in RA and supports the notion of a potential role of IP-10 in the immunopathogenesis of RA.
182
Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study
Lloyd Mayer,William J. Sandborn,Yuriy Stepanov,Karel Geboes,Robert Hardi,Michael Yellin,Xiaolu Tao,Li-An Xu,Luisa Salter-Cid,Sheila Gujrathi,Richard Aranda,Allison Luo +11 more
TL;DR: Anti-IP-10 antibody, BMS-936557, is a potentially effective therapy for moderately-to-severely active UC and higher drug exposure correlated with increasing clinical response and histological improvement.
181
Reliability among central readers in the evaluation of endoscopic findings from patients with Crohn's disease
Reena Khanna,Guangyong Zou,Geert D'Haens,Paul Rutgeerts,John W.D. McDonald,Marco Daperno,Brian G. Feagan,William J. Sandborn,Elena Dubcenco,Larry Stitt,Margaret K. Vandervoort,Allan Donner,Allison Luo,Barrett G. Levesque +13 more
TL;DR: Central reading of CDEIS and SES-CD had ‘substantial’ to ‘almost perfect’ intra-rater and inter- rater reliability; however, the responsiveness of these instruments is yet to be determined.
82
Eldelumab (anti-IP-10) induction therapy for ulcerative colitis: a randomised, placebo-controlled, phase 2b study
William J. Sandborn,Jean-Frederic Colombel,Subrata Ghosh,Bruce E. Sands,Gerald W. Dryden,Xavier Hébuterne,Rupert W. Leong,Brian Bressler,Thomas A. Ullman,Peter L. Lakatos,Walter Reinisch,Li-An Xu,Allison Luo +12 more
TL;DR: The primary endpoint of clinical remission was not achieved with induction treatment with eldelumab 15 or 25 mg/kg in patients with UC, and trends towards clinical remission and response were observed in the overall population and were more pronounced in anti-TNF naïve patients.
Abatacept in subjects who switch from intravenous to subcutaneous therapy: results from the phase IIIb ATTUNE study
Edward C. Keystone,Joel M. Kremer,Anthony H. Russell,Jane Box,Carlos Abud-Mendoza,Mario Alberto Garza Elizondo,Allison Luo,Richard Aranda,Ingrid Delaet,Rene Swanink,Sheila Gujrathi,Michael E. Luggen +11 more
TL;DR: It is demonstrated that patients can switch from long-term monthly intravenous abatacept to a weekly fixed dose of 125 mg SC ab atacept with no increased safety concerns, and further supports SC abatACEpt as an alternative treatment option for patients with RA.
58